06.03.2013 • NewsRoyal DSMDSMEisai

DSM Signs Master Supply Agreement with Eisai

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai, based in Woodcliff Lake, NJ, USA, for the production of sterile products.

The agreement covers the production of eribulin mesylate as well as other developmental drugs.

DSM will be a supplier for eribulin mesylate to the US market. Commercial production is anticipated to start in early 2013. L

No financial details were disclosed.

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.